NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Executive Summary
Biomarker-guided targeted therapy has become a standard approach to oncology R&D, but few new targeted drugs have reached the market for lung cancer. A new wave of research could change that, and improve the outlook for lung cancer treatment.
You may also be interested in...
Clovis Sets Brisk Development Timetable For Lung Cancer Drug
The oncology drug developer expects to file its third generation EGFR inhibitor for the treatment of NSCLC by the end of 2015, CEO Patrick Mahaffy told investors during an R&D day Jan. 27. Investors are enthusiastic about the potential of the drug, which could address a sizeable commercial market.
Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy
Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.
Lung Cancer Drug Development: Prolonging Life v. Treating Symptoms
FDA’s next patient-focused drug development meeting will ask what’s most important when diagnosed with a disease that has a median survival time of a little over a year.